- Strong revenue growth
- Maintained operating income
- Operating cashflow has improved (US$36.3m inflow)
- Attractive valuations given the recent fall in stock price
Here are also some additional points to add to the investment thesis,
- Been meeting analyst expectations as a very solid company.
- Operating cashflow has been on a steady rise over the last 4 quarters.
- Cash pile has increased steadily over the last 4 quarters.
- Medical sector will continue to improve in SEA/Asia region given the improving incomes especially form neighbouring countries that are fast developing and attracting investments.
Outlook - However, on a pure technical front, I have some reservations. As such, I believe Biosensors deserves a Watch outlook with a possible break in downtrend possible. Lately, its stock prices have suffered with the ...
